 The primary purpose of this study is to determine the safety and tolerability of SRT2104 0.25, 0.5, 1.0, and 2.0 gday in type 2 diabetic subjects when administered once daily for 28 consecutive days, and to characterize the pharmacokinetic profile of SRT2104 after a single dose and multiple administrations in type 2 diabetic subjects. 